KR970014765A - 신경보호제를 이용한 이명의 치료 - Google Patents
신경보호제를 이용한 이명의 치료 Download PDFInfo
- Publication number
- KR970014765A KR970014765A KR1019960039978A KR19960039978A KR970014765A KR 970014765 A KR970014765 A KR 970014765A KR 1019960039978 A KR1019960039978 A KR 1019960039978A KR 19960039978 A KR19960039978 A KR 19960039978A KR 970014765 A KR970014765 A KR 970014765A
- Authority
- KR
- South Korea
- Prior art keywords
- compound
- pharmaceutical composition
- hydroxy
- chroman
- pharmaceutically acceptable
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyrrole Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
본 발명은 하기 화학실 (1)의 화합물 또는 그의 약학적으로 허용가능한 염의 치료 효과량을 포함하는 포유동물의 이명 치료용 약학 조성물에 관한 것이다 ;
상기 식에서 , R1내지 R6은 본원에 정의되어 있는 바와 같다.
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
Claims (10)
- 하기 화학식 (1)의 화합물 또는 그의 약학적으로 허용가능한 염의 치료 효과량을 약학적으로 허용가능한 비히클 또는 희석제와 함께 포유동물의 이명 치료용 약학 조성물 :상기 식에서, (a) R2및 R5는 별개이고, R1, R2, R3및 R4는 각각 독립적으로, 수소, C1-C6알킬, 할로, CF3, OH 또는 -OR7이고, R5는 메틸 또는 에틸이거나: 또는 (b) R2및 R5는 함께이고, 크로만-4 올 고리를 형성하고, Rl, R3및 R4는 각각 독립적으로 수소, C1-C6알킬, 할로, CF3, OH 또는 -OR7이고; R6은이고; R7은 메틸, 에틸, 이소프로필 또는 n-프로필이고; R8은 C1-C6알킬, 할로 또는 CF3로 구성된 군에서 독립적으로 선택된 3개 이하의 치환체로 선택적으로 치환된 페닐이고, X는 O, S 및 (CH2)n이고; n은 0, 1, 2 또는 3이다.
- 제1항에 있어서, R2및 R5가 별개이고; R2및 R3가 수소이고; R6이이고; R8이 페닐, 4-할로페닐 또는 4-트리플루오로메틸페닐인 약학 조성물.
- 제2항에 있어서, R5가 1S*, 2S*상대적 입체이성질성을 갖는 메틸인 약학 조성물.
- 제1항에 있어서, R2및 R5가 함께이고, 크로만-4-올 고리를 형성하는 약학 조성물.
- 제4항에 있어서, 상기 크로만-4-올 고리의 C-3 및 C-4 위치에서 3R*, 4S*상대적 입체이성질성을 갖는 약학 조성물.
- 제5항에 있어서, R6이이고; R8이 페닐 또는 4-할로페닐인 약학 조성물.
- 제1항에 있어서, 상기 화합물이 (3R,4S)-3-[4-(4-플루오로페닐)-4-하이드록시-피페리딘-1-일]-크로만-4,7-디올, (1S,2S)-1-(4-하이드록시페닐)-2-(4-하이드록시 -4-페닐피페리딘-1-일)-1-프로판올, 및 이들 화합물의 약학적으로 허용가능한 염으로 구성된 군에서 선택되는 약학 조성물.
- 제7항에 있어서, 상기 화합물이 (1S,2S)-1-(4-하이드록시페닐)-2-(4-하이드록시-4-페닐피페리딘-1-일)-1-프로판올, 이 화합물의 타트타레이트 염 또는 이 화합물의 메실레이트 염인 약학 조성물.
- 제7항에 있어서, 상기 화합물이 (1S,2S)-1-(4-하이드록시페닐)-2-(4-하이드록시-4-페닐피페리딘-1-일)-1-프로판올의 메실레이트 염 삼수화물인 약학 조성물.
- 제7항에 있어서, 상기 화합물이 (3R,4S)-3-[4-(4-플루오로페닐)-4-하이드록시-피페리딘-1-일]-크로만-4,7-디올, 및 이 화합물의 타르타레이트, 락테이트 및 만델레이트 염으로 구성된 군에서 선택되는 약학 조성물.※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US385595P | 1995-09-15 | 1995-09-15 | |
US60/003,855 | 1995-09-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
KR970014765A true KR970014765A (ko) | 1997-04-28 |
Family
ID=21707919
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019960039978A KR970014765A (ko) | 1995-09-15 | 1996-09-14 | 신경보호제를 이용한 이명의 치료 |
Country Status (17)
Country | Link |
---|---|
US (1) | US5716961A (ko) |
EP (1) | EP0768086B1 (ko) |
JP (1) | JP3038155B2 (ko) |
KR (1) | KR970014765A (ko) |
CN (1) | CN1104892C (ko) |
AT (1) | ATE224714T1 (ko) |
AU (1) | AU697679B2 (ko) |
CA (1) | CA2185512C (ko) |
DE (1) | DE69623899T2 (ko) |
DK (1) | DK0768086T3 (ko) |
ES (1) | ES2181853T3 (ko) |
IL (1) | IL119207A (ko) |
MY (1) | MY119375A (ko) |
NZ (1) | NZ299376A (ko) |
PT (1) | PT768086E (ko) |
TW (1) | TW450807B (ko) |
ZA (1) | ZA967746B (ko) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9804885D0 (en) | 1998-03-06 | 1998-04-29 | Merck Sharp & Dohme | Therapeutic combination |
GB9821179D0 (en) * | 1998-09-30 | 1998-11-25 | Merck Sharp & Dohme | Therapeutic use |
FR2787028B1 (fr) * | 1998-12-15 | 2002-10-18 | Aventis Pharma Sa | Utilisation du riluzole dans le traitement des traumatismes acoustiques |
TR200102876T2 (tr) * | 1999-04-07 | 2006-12-21 | Pfizer Products Inc. | Bileşim tedavilerinde CYP2D6 önleyicilerinin kullanılması. |
US6784200B2 (en) * | 2000-10-13 | 2004-08-31 | Bristol-Myers Squibb Pharma Company | Bicyclic and tricyclic amines as modulators of chemokine receptor activity |
US6586446B1 (en) | 1999-10-15 | 2003-07-01 | Bristol-Myers Squibb Company | Bicyclic and tricyclic amines as modulators of chemokine receptor activity |
YU27801A (sh) * | 2000-04-28 | 2003-04-30 | Pfizer Products Inc. | Postupak za dobijanje trihidrata mezilatne soli 1-(4- hidroksifenil)-2-(4-hidroksi-4-fenilpiperidin-1-il)-1-propanola i korisnih intermedijera |
DE10048969A1 (de) * | 2000-08-23 | 2002-03-14 | Mueller Schwefe Gerhard | Verwendung von Flupirtin zur Tinnitusbehandlung |
IL145584A0 (en) * | 2000-10-02 | 2002-06-30 | Pfizer Prod Inc | Nmda nr2b antagonists for treatment |
UA73619C2 (en) * | 2000-12-13 | 2005-08-15 | Pfizer Prod Inc | Stable pharmaceutical compositions of nmda receptor agonist (variants) and method of treatment |
SE0100344D0 (sv) * | 2001-02-05 | 2001-02-05 | Jan Nordmark | New Use |
ATE228358T1 (de) * | 2001-03-21 | 2002-12-15 | Sanol Arznei Schwarz Gmbh | Neue verwendung einer klasse von peptidverbindungen zur behandlung von allodynie oder andere arten von chronischen oder phantomschmerzen |
US6743921B2 (en) | 2002-01-24 | 2004-06-01 | Dsm Catalytica Pharmaceuticals, Inc. | Process for the preparation of nonracemic syn-1-(4-hydroxy-phenyl)-2-(4-hydroxy-4-phenyl-piperidin-1-yl)-1-propanol compounds |
US7589110B2 (en) * | 2002-09-06 | 2009-09-15 | Durect Corporation | Delivery of modulators of glutamate-mediated neurotransmission to the inner ear |
US7785653B2 (en) * | 2003-09-22 | 2010-08-31 | Innovational Holdings Llc | Method and apparatus for loading a beneficial agent into an expandable medical device |
US20060063802A1 (en) * | 2004-03-29 | 2006-03-23 | Matthieu Guitton | Methods for the treatment of tinnitus induced by cochlear excitotoxicity |
US9072662B2 (en) | 2004-03-29 | 2015-07-07 | Auris Medical Ag | Methods for the treatment of tinnitus induced by cochlear excitotoxicity |
US8268866B2 (en) | 2004-03-29 | 2012-09-18 | Matthieu Guitton | Methods for the treatment of tinnitus induced by cochlear excitotoxicity |
NZ566062A (en) * | 2005-09-28 | 2009-08-28 | Auris Medical Ag | Pharmaceutical compositions for the treatment of inner ear disorders comprising an arylcycloalkylamine such as ketamine and a biocompatible polymer |
US20090069419A1 (en) * | 2007-09-07 | 2009-03-12 | Bernd Jandeleit | Masked carboxylate neopentyl sulfonyl ester cyclization release prodrugs of acamprosate, compositions thereof, and methods of use |
WO2009033079A1 (en) * | 2007-09-07 | 2009-03-12 | Xenoport, Inc. | Externally masked neopentyl sulfonyl ester cyclization release prodrugs of acamprosate, compositions thereof, and methods of use |
US20090099253A1 (en) * | 2007-10-15 | 2009-04-16 | Xenoport, Inc. | Internally Masked Neopentyl Sulfonyl Ester Cyclization Release Prodrugs of Acamprosate, Compositions Thereof, and Methods of Use |
US8454877B2 (en) * | 2009-04-03 | 2013-06-04 | Pelican Products, Inc. | Method and apparatus for molding an article |
WO2011145062A1 (en) | 2010-05-21 | 2011-11-24 | Link Research & Grants Corporation | Treatment of tinnitus and related auditory dysfunctions |
EP2621475A1 (en) | 2010-10-02 | 2013-08-07 | Link Research&Grants Corporation | Treatment of tinnitus and related auditory dysfunctions |
US8648198B2 (en) | 2011-01-19 | 2014-02-11 | Cold Spring Harbor Laboratory | Phenylethanolamine-based NMDA receptor antagonists |
US8920855B1 (en) | 2012-10-30 | 2014-12-30 | Setem Hemth, Inc | Methods of topically treating tinnitus and related disorders |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1990014087A1 (en) * | 1989-05-17 | 1990-11-29 | Pfizer Inc. | 2-piperidino-1-alkanol derivatives as antiischemic agents |
JPH0788355B2 (ja) * | 1991-04-18 | 1995-09-27 | フアイザー・インコーポレイテツド | フェノール性2―ピペリジノ―1―アルカノールのプロドラグエステル |
EP0542689B1 (en) * | 1991-11-15 | 1998-09-23 | Phafag Aktiengesellschaft | Use of 1-(aminoalkyl)-3-quinoxaline-2-on derivatives for the preparation of neuroprotective compositions |
GB9400680D0 (en) * | 1994-01-14 | 1994-03-09 | Sandoz Ltd | Improvements in or relating to organic compounds |
-
1996
- 1996-06-11 TW TW085107025A patent/TW450807B/zh not_active IP Right Cessation
- 1996-08-27 AT AT96306198T patent/ATE224714T1/de not_active IP Right Cessation
- 1996-08-27 DE DE69623899T patent/DE69623899T2/de not_active Expired - Fee Related
- 1996-08-27 ES ES96306198T patent/ES2181853T3/es not_active Expired - Lifetime
- 1996-08-27 DK DK96306198T patent/DK0768086T3/da active
- 1996-08-27 EP EP96306198A patent/EP0768086B1/en not_active Expired - Lifetime
- 1996-08-27 PT PT96306198T patent/PT768086E/pt unknown
- 1996-09-05 IL IL11920796A patent/IL119207A/en not_active IP Right Cessation
- 1996-09-09 US US08/709,996 patent/US5716961A/en not_active Expired - Fee Related
- 1996-09-12 JP JP8262343A patent/JP3038155B2/ja not_active Expired - Fee Related
- 1996-09-13 CN CN96112326A patent/CN1104892C/zh not_active Expired - Fee Related
- 1996-09-13 MY MYPI96003783A patent/MY119375A/en unknown
- 1996-09-13 ZA ZA9607746A patent/ZA967746B/xx unknown
- 1996-09-13 NZ NZ299376A patent/NZ299376A/en unknown
- 1996-09-13 AU AU65635/96A patent/AU697679B2/en not_active Ceased
- 1996-09-13 CA CA002185512A patent/CA2185512C/en not_active Expired - Fee Related
- 1996-09-14 KR KR1019960039978A patent/KR970014765A/ko not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
TW450807B (en) | 2001-08-21 |
NZ299376A (en) | 2000-07-28 |
DE69623899D1 (de) | 2002-10-31 |
EP0768086B1 (en) | 2002-09-25 |
CA2185512A1 (en) | 1997-03-16 |
CN1149454A (zh) | 1997-05-14 |
DE69623899T2 (de) | 2003-01-23 |
JPH09124482A (ja) | 1997-05-13 |
IL119207A0 (en) | 1996-12-05 |
AU697679B2 (en) | 1998-10-15 |
CA2185512C (en) | 2000-08-08 |
ATE224714T1 (de) | 2002-10-15 |
ES2181853T3 (es) | 2003-03-01 |
US5716961A (en) | 1998-02-10 |
ZA967746B (en) | 1998-03-13 |
AU6563596A (en) | 1997-03-20 |
JP3038155B2 (ja) | 2000-05-08 |
IL119207A (en) | 2004-05-12 |
DK0768086T3 (da) | 2002-10-14 |
MY119375A (en) | 2005-05-31 |
CN1104892C (zh) | 2003-04-09 |
MX9603819A (es) | 1997-07-31 |
EP0768086A1 (en) | 1997-04-16 |
PT768086E (pt) | 2003-01-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR970014765A (ko) | 신경보호제를 이용한 이명의 치료 | |
RU2203274C2 (ru) | Спироциклические ингибиторы металлопротеаз | |
KR970705542A (ko) | 신경보호성 3-(피페리디닐-1)-크로만-4,7-디올 및 1-(4-하이드로페닐)-2-(피페리디닐-1)-알칸올 유도체(neuroprotective 3-(piperidinyl-1)-chroman-4,7-diol and 1-(4-hydrophenyl)-2-(piperidinyl-1)-alkanol derivatives | |
NO991700L (no) | Benzimidazol-2-karbamater for behandling av virusinfeksjoner og cancer | |
JP2007517846A5 (ko) | ||
RU97102362A (ru) | Нейрозащитные производные 3-(пиперидинил-1)-хроман-4,7-диола и 1-(4- гидроксифенил)-2-(пиперидинил-1)-алканола | |
ATE282410T1 (de) | Thyromimetika als mittel gegen fettleibigkeit | |
PT97710A (pt) | Processo para a preparacao de novos derivados da amino-piperidina,da amino-pirrolidina e de amino-per-hidroazepina | |
RU2007147344A (ru) | Новые производные 2-азетидинона для лечения гиперлипидемических заболеваний | |
KR930701402A (ko) | N- 하이드로 카르빌 -4- 치환된 피페리딘, 이들의 제조 방법 및 이들의 칼슘 차단제로서의 용도 | |
RU94044436A (ru) | Способы подавления атрофии кожи и влагалища | |
FI952481A (fi) | Substituoituja 3-(aminoalkyyliamino)-1,2-bentsisoksatoleja ja niihin liittyviä yhdisteitä | |
PT863136E (pt) | Derivados de azetidina e de pirrolidina | |
PT992509E (pt) | Novos derivados macrolidos | |
DK0984019T3 (da) | C11-carbamater fra antibakterielle macrolider | |
BR8303091A (pt) | Processo para a preparacao de derivados de hidrozialcinil-azolilo, composicoes fungicidas, processos para o combate de fungos e para a preparacao de composicoes | |
KR910004191A (ko) | 신질환치료제 | |
KR950702554A (ko) | 소염제로서 유용한 2-헤테로시클릭-5-히드록시-1,3-피리미딘 (2-Heterocyclic-5-Hydroxy-1,3-Pyrimidines Useful as Antiinflammatory Agents) | |
KR960704878A (ko) | 광학 활성 이미다졸리딘온 유도체 및 이의 제조방법 (Optically active imidazolidinone derivative and process for producing the same) | |
KR900012925A (ko) | 인돌 유도체 | |
KR960702456A (ko) | 4-(p-플로오로페닐)-3-[(3,4-(메틸렌디옥시)페녹시)메틸]피페리딘의 n-p-할로벤조일메틸 유도체(n-p-halobenzoylmethyl derivatives of 4-(p-fluorophenyl)-3-[[3,4-(methylenedioxy)phenoxy]methyl]piperidine) | |
PT1209166E (pt) | Novos derivados de a-500359 | |
FI95243B (fi) | Typpiheterosyklien substituoidut 2-propenyylijohdannaiset | |
KR970705385A (ko) | 뼈 치료법 및 골절 치유법(methods for bone healing and fracture repair) | |
KR920700640A (ko) | 혈당 저하제 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E601 | Decision to refuse application |